Conclusion
These findings indicate that COVID-19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission, acute renal failure and venous thromboembolism than matched comparators. These risks may be largely mediated by comorbidities, except for the risk of venous thromboembolism. Patients with a systemic rheumatic disease and COVID-19 should be closely monitored for thrombotic complications.
Refer to the full study for all source material.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Excerpted and adapted from: D’Silva KM, Jorge A, Cohen A, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A U.S. multicenter, comparative cohort study. Arthritis Rheumatol. 2021 Jun;73(6):914–920.